Other cardiometabolic health — Revenue
Products & Services · RevenueEli Lilly Other cardiometabolic health — Revenue decreased by 4.4% to $1.02B in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful lifecycle management or market penetration of secondary therapeutic assets, while a decrease may suggest product maturity, increased competition, or a strategic shift in portfolio focus.
Detailed definition
This metric represents the total net sales generated from the company's secondary portfolio of cardiometabolic therapeut...
Peer comparison
Comparable to secondary metabolic or cardiovascular product line revenues reported by major pharmaceutical peers, often categorized under 'established products' or 'specialty care' segments.
Metric ID:
lly_segment_other_cardiometabolic_health_revenueHistorical Data
13 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $124.23M | $124.23M | $124.23M | $124.23M | $136.60M | $141.90M | $1.03B | $1.17B | $1.05B | $944.80M | $980.40M | $1.06B | $1.02B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +10.0% | +3.9% | +623.3% | +13.6% | -10.0% | -9.9% | +3.8% | +8.5% | -4.4% |
| YoY Change | — | — | — | — | +10.0% | +14.2% | — | +753.1% | +639.0% | -7.9% | -15.9% | +1.4% | — |
Range$124.23M – $1.17B
CAGR+101.5%
Avg YoY Growth+199.1%
Median YoY Growth+10.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other cardiometabolic health — revenue?
- Eli Lilly (LLY) reported other cardiometabolic health — revenue of $1.02B in Q4 2025.
- What does other cardiometabolic health — revenue mean?
- The total revenue generated by the company's secondary or niche cardiometabolic health pharmaceutical products.